At that time, if a large amount of PlGF is released from the BPH tissue around the cancer, it forms a heterodimer with VEGF derived from the cancer, inhibits the binding of VEGF with VEGFR‐2, and subsequently inhibits angiogenesis and cancer proliferation. Here, KDR is linked to cancer.